Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab extension study in multiple sclerosis
NL-OMON41482Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of alemtuzumab in multiple sclerosis (MS) (2 cohorts), sponsored by Sanofi. Started Nov 2010; status: active, not recruiting.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON41482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41482.